NASDAQ:SELB Selecta Biosciences (SELB) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.88▼$1.2652-Week Range N/AVolume2.77 million shsAverage Volume979,585 shsMarket Capitalization$136.76 millionP/E RatioN/ADividend YieldN/APrice Target$2.80 Stock AnalysisStock Analysis Get Selecta Biosciences alerts: Email Address Selecta Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside∞ Upside$2.80 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.99Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.33) to ($0.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.80 out of 5 starsMedical Sector453rd out of 936 stocksBiotechnology Industry1st out of 11 stocks 3.3 Analyst's Opinion Consensus RatingSelecta Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageSelecta Biosciences has received no research coverage in the past 90 days.Read more about Selecta Biosciences' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for SELB. Previous Next 0.0 Dividend Strength Dividend YieldSelecta Biosciences does not currently pay a dividend.Dividend GrowthSelecta Biosciences does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSelecta Biosciences has received a 69.16% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Selecta Biosciences is -0.99. Previous Next N/A News and Social Media Coverage Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Selecta Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders31.20% of the stock of Selecta Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions41.95% of the stock of Selecta Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Selecta Biosciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Selecta Biosciences are expected to grow in the coming year, from ($0.33) to ($0.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Selecta Biosciences is -4.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Selecta Biosciences is -4.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Selecta Biosciences Stock (NASDAQ:SELB)Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.Read More Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here SELB Stock News HeadlinesMay 6, 2024 | msn.comCraig David says Leigh Francis' Bo Selecta! skit 'sent him down a dark road'January 23, 2024 | yahoo.comSelb, Germany - Weather Forecasts | Maps | News - Yahoo WeatherJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.December 15, 2023 | investing.comCartesian Therapeutics Inc (RNAC)November 14, 2023 | finance.yahoo.comFurther weakness as Selecta Biosciences (NASDAQ:SELB) drops 17% this week, taking five-year losses to 85%November 13, 2023 | bizjournals.comPared-down Selecta merges with Maryland biotechNovember 13, 2023 | msn.comSelecta Biosciences Merges With Cartesian To Focus On Autoimmune Cell TherapyNovember 13, 2023 | markets.businessinsider.comSelecta Biosciences Merges With Cartesian Therapeutics In All-stock DealJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.November 11, 2023 | benzinga.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Selecta Biosciences, Inc. (NASDAQ: SELB) and Encourages Investors to Contact the FirmNovember 10, 2023 | morningstar.comSelecta Biosciences Inc SELBOctober 31, 2023 | marketwatch.comSelecta Biosciences in Deal to Transfer Manufacturing, Development Rights of Sel-212 TreatmentOctober 31, 2023 | finance.yahoo.comSelecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner SobiOctober 25, 2023 | msn.comSelecta Biosciences files for $200M mixed shelfAugust 19, 2023 | msn.comMizuho Maintains Selecta Biosciences (SELB) Buy RecommendationAugust 19, 2023 | msn.comSVB Leerink Downgrades Selecta Biosciences (SELB)August 18, 2023 | markets.businessinsider.comAnalyst Ratings for Selecta BiosciencesAugust 18, 2023 | msn.comNeedham Maintains Selecta Biosciences (SELB) Buy RecommendationSee More Headlines Receive SELB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Selecta Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/17/2023Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:SELB CUSIPN/A CIK1453687 Webselectabio.com Phone(617) 923-1400Fax617-924-3454Employees64Year FoundedN/APrice Target and Rating Average Stock Price Target$2.80 High Stock Price Target$5.00 Low Stock Price Target$1.00 Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$35.38 million Net Margins-72.04% Pretax Margin-73.23% Return on Equity-44.13% Return on Assets-22.00% Debt Debt-to-Equity Ratio0.21 Current Ratio4.18 Quick Ratio4.18 Sales & Book Value Annual Sales$110.78 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow9.91 Book Value$0.61 per share Price / BookN/AMiscellaneous Outstanding Shares155,200,000Free Float106,780,000Market Cap$136.76 million OptionableOptionable Beta0.84 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesDr. Carsten Brunn Ph.D. (Age 52)CEO, President & Director Comp: $914.66kMr. Blaine T. Davis (Age 49)Chief Financial Officer Comp: $370.34kDr. Lloyd Johnston Ph.D. (Age 55)Chief Operating Officer Comp: $589.81kDr. Takashi Kei Kishimoto Ph.D. (Age 63)Chief Scientific Officer Comp: $599.81kDr. Peter G. Traber M.D. (Age 68)Chief Medical Officer Comp: $670.29kDr. Ulrich H. von Andrian-Werburg M.D.Ph.D., Co-Founder and Co-Chair of the Scientific Advisory BoardMr. Matthew Bartholomae J.D.General Counsel & SecretaryMs. Kristen BaldwinChief People OfficerMs. Ann K. Donohue CPA (Age 41)VP of Finance & Controller Comp: $286.97kMore ExecutivesKey CompetitorsCytomX TherapeuticsNASDAQ:CTMXLianBioNASDAQ:LIANPHAXIAM TherapeuticsNASDAQ:PHXMRedHill BiopharmaNASDAQ:RDHLPolarityTENASDAQ:PTEIQView All CompetitorsInsidersCarsten BrunnSold 2,932 sharesTotal: $3,107.92 ($1.06/share)Peter G TraberSold 705 sharesTotal: $747.30 ($1.06/share) SELB Stock Analysis - Frequently Asked Questions How were Selecta Biosciences' earnings last quarter? Selecta Biosciences, Inc. (NASDAQ:SELB) released its quarterly earnings results on Thursday, August, 17th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.05. The business earned $5.25 million during the quarter, compared to analysts' expectations of $9.90 million. Selecta Biosciences had a negative trailing twelve-month return on equity of 44.13% and a negative net margin of 72.04%. When did Selecta Biosciences IPO? Selecta Biosciences (SELB) raised $64 million in an IPO on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank and Stifel served as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers. What other stocks do shareholders of Selecta Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Selecta Biosciences investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rigel Pharmaceuticals (RIGL), Novavax (NVAX) and Dynavax Technologies (DVAX). This page (NASDAQ:SELB) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Selecta Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Selecta Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
